New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 9, 2012
08:41 EDTAVNR, IPXLAvanir sues Impax over planned Nuedexta generic, Bloomberg reports
Avanir Pharmaceuticals (AVNR) is suing Impax Laboratories (IPXL) for allegedly infringing a new patent for the drug Nuedexta and planning to market a generic version of the drug before the patent expires in 2023, reported Bloomberg, citing a complaint filed in a federal court in Delaware. Reference Link
News For AVNR;IPXL From The Last 14 Days
Check below for free stories on AVNR;IPXL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 22, 2014
18:18 EDTAVNROn The Fly: After Hours Movers
Subscribe for More Information
16:41 EDTAVNRAvanir files automatic mixed securities shelf
11:02 EDTAVNROptions with decreasing implied volatility
Subscribe for More Information
06:17 EDTAVNRAvanir implied volatility of 91 at lower end of index mean range
Subscribe for More Information
September 17, 2014
09:06 EDTIPXLImpax granted extension of Rytary FDA review date to January 9, 2015
Subscribe for More Information
September 15, 2014
17:09 EDTAVNROn The Fly: Closing Wrap
Stocks on Wall Street were mixed to begin the week, as the Dow managed to register mild gains but the Nasdaq was weighed down by slides in a number of so-called "momentum stocks" like Tesla (TSLA). Investors may remain cautious in the next two sessions ahead of the Fed's much anticipated rate decision and accompanying statement, which is due Wednesday. ECONOMIC EVENTS: In the U.S., New York Fed's Empire state survey for September rose to a five-year high of 27.54. Industrial production unexpectedly dipped 0.1% in August from a downwardly revised 0.2% July gain, missing the forecast for a rise of 0.3%. Capacity utilization dropped to 78.8% last month from 79.1% previously. In China, industrial output increased 6.9% in August versus the same period a year earlier, which was its weakest advance, excluding months that fell during New Year holidays, since December 2008. Chinese retail sales growth for August came in at 11.9%, missing the consensus estimate. COMPANY NEWS: Shares of Apple (AAPL) edged down 3c, or 0.03%, to $101.63 despite the company's announcement that a record 4M iPhone 6 and iPhone 6 Plus pre-orders were placed in the first 24 hours that ordering was available. Demand for the new phones exceeds the initial pre-order supply, the company added, stating that delivery of "many" iPhone pre-orders have been pushed out to October... Microsoft (MSFT) slid 45c, or 0.97%, to $46.24 after the company confirmed an agreement to acquire Mojang, the developer for the "Minecraft" video game franchise, for $2.5B... MAJOR MOVERS: Among the notable gainers was Avanir Pharmaceuticals (AVNR), which surged $5.75, or 85.31%, to $12.49 and was upgraded to Buy from Hold at Jefferies after the company announced results from its phase II clinical trial evaluating the safety and efficacy of its treatment of agitation in patients with Alzheimer's disease. Also higher was SABMiller (SBMRY), which jumped $4.72, or 8.5%, to $60.26 after the Wall Street Journal said that ABInBev (BUD) was looking to obtain financing for an acquisition of the U.K.-based brewer and Heineken (HEINY) confirmed that it rebuffed SABMiller's approach regarding a potential transaction. The news of potential consolidation in the space also drove other beer makers highers, with Molson Coors (TAP) rising $4.20, or 5.85%, to $76.00 and Boston Beer (SAM) gaining 71c, or 0.33%, to $218.47. Among the noteworthy losers was Tesla (TSLA), which dropped $25.34, or 9.08%, to $253.86 after Morgan Stanley analyst Adam Jones wrote that he agrees with the assertion of Tesla's CEO Elon Musk that the company's stock may have gotten ahead of itself. Also lower were shares of NPS Pharmaceuticals (NPSP), which fell $5.42, or 16.56%, to $27.28 after Oppennheimer and Jefferies stated that approval of its Natpara drug for hypoparathyroidism could be delayed after concerns were raised during an FDA panel meeting, even though the advisors were in favor of approving the drug. INDEXES: The Dow rose 43.63, or 0.26%, to 17,031.14, the Nasdaq dropped 48.70, or 1.07%, to 4,518.90, and the S&P 500 declined 1.41, or 0.07%, to 1,984.13.
13:11 EDTAVNRAvanir upgraded to Buy from Hold at Jefferies
12:31 EDTAVNROn The Fly: Midday Wrap
Subscribe for More Information
10:36 EDTAVNRHigh option volume stocks
Subscribe for More Information
10:21 EDTAVNRAvanir price target raised to $12.20 on positive Alzheimer data at Cowen
Subscribe for More Information
09:47 EDTAVNRAvanir price target raised to $17 from $13 at Piper Jaffray
09:35 EDTAVNRActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL TSLA RSH YHOO GILD TWTR AVNR NFLX BAC C
08:32 EDTAVNRAvanir announces positive Phase II results for AVP-923
Subscribe for More Information
06:13 EDTAVNRStocks with implied volatility top IV index mean; AMD AVNR
Subscribe for More Information
September 11, 2014
11:29 EDTAVNROptions with increasing implied volatility
Options with increasing implied volatility: VNET AVNR GPRO RAX FTR JDSU PSEC APD SYY GGP

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use